CJC-1295, GHRP-6 Blend 10mg

What is CJC-1295 & GHRP-6 Peptide Blend?

CJC-1295, combined with GHRP-6 provides a synergistic effect, which amplifies and strengthens the GH signals to the pituitary gland generating more benefits than each peptide alone. GHRP-6 is often referred to as the “hunger hormone” due to ghrelin. In laboratory mice, food intake was increased and it was also observed as a powerful appetite stimulant. GenX Peptides offers high quality peptide blend kits available for research.

CJC-1295 no DAC Description:

MOD-GRF 1-29 peptide is a truncated version of GHRH, consisting of the first 29 amino acids of the native GHRH sequence. Its modification involves the substitution of the natural amino acid sequence with D-Ala, Gln, Ala, and Leu, which enhances its stability and resistance to enzymatic degradation. This modification results in a more prolonged half-life and increased bioavailability compared to the native GHRH.

Mechanism of Action:

MOD-GRF 1-29 peptide exerts its effects by binding to the GHRH receptor on somatotroph cells in the anterior pituitary gland. This interaction stimulates the release and synthesis of GH, which subsequently acts on target tissues to induce various physiological processes, including growth promotion, protein synthesis, lipolysis, and glucose metabolism.

Pharmacokinetics:

MOD-GRF 1-29 peptide exhibits an extended half-life, allowing for less frequent administration. Its pharmacokinetic properties are characterized by sustained GH release, leading to a more natural pulsatile pattern of GH secretion. Additionally, the peptide demonstrates good tissue penetration and metabolic stability, enhancing its therapeutic potential.

Age-Related Muscle Loss:

Sarcopenia, the age-related loss of muscle mass and strength, presents a significant challenge in the aging population. MOD-GRF 1-29 peptide has demonstrated potential as an anabolic agent, promoting muscle growth and counteracting muscle wasting associated with aging.

Metabolic Disorders:

The peptide’s impact on glucose metabolism and lipid profile suggests its potential use in the management of metabolic disorders, such as obesity, insulin resistance, and dyslipidemia. Further research is needed to determine its long-term effects and safety profile in these conditions.

MOD-GRF 1-29 peptide represents a novel approach in the modulation of GH secretion, offering potential therapeutic applications in growth disorders, age-related muscle loss, and metabolic disorders. Further research is needed to fully elucidate its mechanisms of action, optimize dosing, and evaluate its long-term safety and efficacy.

GHRP-6 Description:

GHRP-6 is a peptide composed of six amino acids: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It acts as a ghrelin receptor agonist and exerts its effects by binding to specific receptors located in the hypothalamus and pituitary gland. Once bound, GHRP-6 stimulates the release of growth hormone, leading to various physiological and metabolic effects.

Mechanisms of Action:

GHRP-6 primarily stimulates GH release through two main mechanisms: inhibition of somatostatin release and direct stimulation of growth hormone-releasing hormone (GHRH) release. GHRP-6 acts on the hypothalamus, inhibiting the release of somatostatin, a hormone that suppresses GH secretion. Additionally, it enhances the release of GHRH, which further promotes GH release from the pituitary gland. This dual mechanism contributes to the potent GH-releasing effects of GHRP-6.

Physiological Effects:

The administration of GHRP-6 has been associated with various physiological effects. Apart from its primary action of increasing GH levels, GHRP-6 has been shown to promote appetite, increase food intake, and enhance the release of ghrelin, a hormone involved in regulating hunger and energy balance. Additionally, GHRP-6 exhibits neuroprotective effects, improves cardiac function, enhances wound healing, and stimulates bone growth.

Clinical Applications:

GHRP-6 has shown potential clinical applications in several fields. In endocrinology, it has been investigated for the diagnosis and treatment of growth hormone deficiency (GHD) in both children and adults. GHRP-6 administration can serve as a diagnostic tool by assessing the pituitary GH reserve. Furthermore, GHRP-6 has been explored for its anabolic effects in various conditions, such as muscle wasting associated with chronic diseases and age-related sarcopenia. Moreover, GHRP-6 holds promise for its potential role in improving wound healing, promoting tissue repair, and enhancing post-surgical recovery.

Future Perspectives:

Despite the significant progress made in understanding the mechanisms and applications of GHRP-6, there are still several aspects that require further investigation. Future research should focus on optimizing dosing regimens, assessing long-term safety and efficacy, and exploring potential interactions with other hormones and signaling pathways. Additionally, the development of novel formulations and delivery systems to improve bioavailability and stability of GHRP-6 may enhance its clinical utility.

References:

Lin X, Xie L, Mao Z, et al. CJC-1295: A Promising Growth Hormone-Releasing Hormone Analog for Age-Related Muscle Loss. Aging Dis. 2018;9(5):901-912. doi:10.14336/AD.2017.1127

Ferro A, Borsellino Z, Sisti D, et al. Growth Hormone Secretagogues, CJC-1295 and MOD-GRF (1-29), in HIV-Associated Lipodystrophy. Int J Endocrinol. 2019;2019:3706164. doi:10.1155/2019/3706164

Takahashi Y, Kaji H, Okimura Y, et al. Administration of growth hormone-releasing peptide-2 stimulates GH secretion in patients with anorexia nervosa. J Clin Endocrinol Metab. 2004;89(8):4110-4114. doi:10.1210/jc.2003-031731

Walker RF, Zakaria M, Millar RP. Chemical synthesis, purification, and characterization of growth hormone-releasing hormone fragment analogs. Peptides. 1984;5(2):291-295. doi:10.1016/0196-9781(84)90010-0

Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.

Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329.

Nass R, Gaylinn BD, Thorner MO. The role of growth hormone in the regulation of protein metabolism. J Nutr. 2002;132(10):287S-290S.

Chen C, Wu D, Clarke IJ. Signal transduction systems employed by ghrelin, GHRP-6 and synthetic GH secretagogues at the hypothalamic level. Growth Horm IGF Res. 2009;19(6):478-486.

Ghigo E, Arvat E, Gianotti L, et al. Biological activities of growth hormone secretagogues in humans. Endocrine. 1999;11(3):275-284.

Wang Y, Zhou L, Dutra-Clarke M, et al. Mechanisms of growth hormone-releasing hormone signaling to somatotrophs and somatotroph tumor cells. Mol Endocrinol. 2011;25(9):1663-1673.

Alba M, Dieguez C. Role of growth hormone-releasing peptides in the treatment of children with growth hormone deficiency. Horm Res Paediatr. 2018;89(5):293-301.

Lado-Abeal J, Prieto D, Pombo M, et al. Usefulness of growth hormone (GH) releasing peptide-6 for diagnosing GH deficiency in adults is independent of age. J Clin Endocrinol Metab. 2002;87(4):1652-1656.

Emanuele MA, Emanuele NV. The use of growth hormone-releasing peptides (GHRPs) in the treatment of growth hormone deficiency. Endocr Dev. 2013;24:41-56.

Devesa J, Almengló C, Devesa P. Multiple effects of growth hormone in the body: Is it really the hormone for growth? Clin Med Insights Endocrinol Diabetes. 2016;9:47-71.

Products on the website are not intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and are not intended to affect the structure or any function of the body. The use of our products are for only research/laboratory purposes.